These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 10179922)

  • 21. Prophylaxis and treatment of NSAID-induced gastropathy.
    Ament PW; Childers RS
    Am Fam Physician; 1997 Mar; 55(4):1323-6, 1331-2. PubMed ID: 9092293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
    Maetzel A; Ferraz MB; Bombardier C
    Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic consequences of NSAID-induced gastrointestinal damage.
    de Pouvourville G; Tasch RF
    Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
    Plosker GL; Lamb HM
    Pharmacoeconomics; 1999 Jul; 16(1):85-98. PubMed ID: 10539124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
    Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
    Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
    Greene JM; Winickoff RN
    Arch Intern Med; 1992 Oct; 152(10):1995-2002. PubMed ID: 1417372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis.
    Fries JF; Murtagh KN; Bennett M; Zatarain E; Lingala B; Bruce B
    Arthritis Rheum; 2004 Aug; 50(8):2433-40. PubMed ID: 15334455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost effectiveness of misoprostol therapy in prevention of NSAID-induced stomach ulcers].
    Schwarz B
    Wien Klin Wochenschr; 1995; 107(12):366-72. PubMed ID: 7631507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
    Knill-Jones RP
    Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Critical evaluation of economic analysis exemplified by preventive misoprostol administration in antirheumatic drug-induced gastropathy].
    Stucki G; Sangha O
    Z Rheumatol; 1994; 53(1):37-45. PubMed ID: 8165876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.
    Altman R; Barkin RL
    Postgrad Med; 2009 Mar; 121(2):139-47. PubMed ID: 19332972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and NSAID induced gastropathy.
    Zeidler H
    J Rheumatol Suppl; 1991 Mar; 28():2-5. PubMed ID: 2038013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM; Bytzer P
    Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal colic in adults: NSAIDs and morphine are effective for pain relief.
    Prescrire Int; 2009 Oct; 18(103):217-21. PubMed ID: 19882796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
    Davis R; Yarker YE; Goa KL
    Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Present position in the prevention and therapy of NSAID-induced ulcers].
    Lehmann FS; Beglinger C
    Schweiz Med Wochenschr; 1999 Jul; 129(29-30):1073-80. PubMed ID: 10464910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.